FDA approves rusfertide (Mimrylo) for adults with polycythemia vera

Ovaj se unos prikazuje na engleskom dok se njegov prijevod ne ažurira.

The FDA approved Mimrylo (rusfertide) for adults with polycythemia vera, a disorder that causes excess red blood cell production. It is the first approved medicine for this condition that mimics the iron-regulating hormone hepcidin. Approval was based on the 293-participant VERIFY trial, which found a reduced need for blood-removal procedures (phlebotomy) compared with placebo. Injection-site reactions and anemia were the most common adverse reactions.